Tesamorelin is a synthetic analog of GHRH (growth hormone releasing hormone) consisting of the full 44-amino acid sequence with a trans-3-hexenoic acid modification at the N-terminus that increases stability. It is FDA-approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy (abnormal fat distribution in HIV patients on antiretroviral therapy). This FDA approval, backed by Phase 3 clinical trial data, makes tesamorelin one of the most clinically validated GHRH analogs available.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy — abnormal visceral fat accumulation in HIV patients. Off-label, it is researched for age-related visceral fat reduction in non-HIV adults. Its mechanism — GHRH receptor activation driving preferential visceral lipolysis via GH — is equally applicable to both populations.
How Does Tesamorelin Work?
Tesamorelin activates the GHRH receptor (GHRHr) in the anterior pituitary — the same receptor targeted by CJC-1295 (Mod GRF 1-29), but through the complete 44-amino acid sequence rather than the truncated 29-amino acid version. The N-terminal modification extends half-life from the 7–10 minutes of native GHRH to approximately 60–90 minutes.
This longer half-life and use of the full GHRH sequence means tesamorelin maintains the complete GHRH-receptor interaction, potentially producing a more physiologically complete signal than shorter analogs. The downstream effect is pulsatile GH release from the pituitary, with subsequent IGF-1 elevation.
The mechanism is relevant for visceral fat specifically: GH acts on visceral adipose tissue to preferentially mobilise visceral fat deposits. This selectivity — GH's known affinity for visceral lipolysis — is the basis for tesamorelin's approval in HIV lipodystrophy and its research interest for age-related visceral adiposity.
Clinical Data and FDA Approval
Tesamorelin's FDA approval rests on two Phase 3 clinical trials in HIV-positive adults with excess visceral fat from antiretroviral therapy. Both trials demonstrated statistically significant reductions in visceral adipose tissue (VAT) measured by CT scan — approximately 15–18% reduction compared to placebo at 26 weeks.
Secondary outcomes included improved lipid profiles, reduced waist circumference, and quality of life improvements. IGF-1 increased significantly from baseline. The trials also documented the side effect profile: increased IGF-1-related concerns (potential growth promotion), glucose metabolism effects, and the expected GH-related water retention.
Off-label research use of tesamorelin has extended to general age-related visceral fat accumulation — the mechanism is equivalent and the population (any adult with elevated visceral fat) is substantially larger than the HIV lipodystrophy indication.
What Is the Recommended Tesamorelin Dosage?
| Protocol | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| FDA-approved (HIV lipodystrophy) | 2 mg/day | SubQ abdomen | Consistent time daily | Approved dose |
| Off-label visceral fat | 1–2 mg/day | SubQ | Fasted AM or before sleep | Community protocol |
| Combined with Ipamorelin | 1 mg tesamorelin + 200 mcg Ipamorelin | SubQ | Fasted | Synergistic GH pulse |
Side Effects and Considerations
Tesamorelin's side effect profile is well-characterised from Phase 3 clinical trials — an advantage over research peptides with only preclinical data.
**Injection site reactions** are common — erythema, pruritus, pain. More frequent with abdominal injection. Rotating injection sites within the abdomen reduces cumulative site reactions.
**Fluid retention and joint pain:** Standard GH-related effects — oedema, arthralgias, carpal tunnel-like symptoms. Dose-dependent and usually resolve with dose reduction or discontinuation.
**Glucose metabolism:** Tesamorelin elevates GH, which has insulin-antagonising effects. Fasting glucose may increase. Individuals with diabetes or pre-diabetes require monitoring.
**IGF-1 elevation:** More pronounced with 2 mg daily than with typical CJC-1295 protocols. Monitoring IGF-1 levels is advisable for extended use.
**Contraindications from the label:** Active malignancy, active tumours, disruption of the hypothalamic-pituitary axis from prior surgery/radiation. These are standard GHRH analog concerns.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Tesamorelin is FDA-approved for HIV-associated lipodystrophy — abnormal visceral fat accumulation in HIV patients. Off-label, it is researched for age-related visceral fat reduction in non-HIV adults. Its mechanism — GHRH receptor activation driving preferential visceral lipolysis via GH — is equally applicable to both populations.
Both are GHRH analogs. Tesamorelin uses the full 44-amino acid GHRH sequence with N-terminal modification; CJC-1295 (Mod GRF 1-29) uses the truncated 29-amino acid biologically active fragment. Tesamorelin has FDA approval and Phase 3 clinical trial data behind it. CJC-1295 is more commonly used in community protocols. Both activate the GHRH receptor to produce pulsatile GH.
Yes — this is its primary clinically validated effect. Phase 3 trials showed 15–18% reduction in visceral adipose tissue (measured by CT) compared to placebo. The mechanism is GH's preferential stimulation of visceral lipolysis. Results are lost when tesamorelin is discontinued — the visceral fat reduction is maintained only with continued treatment.
Different tools with different evidence bases. Tesamorelin has Phase 3 human trial data; Sermorelin has older FDA approval history (now lapsed) but less specific visceral fat evidence. Tesamorelin's 2 mg dose produces stronger GH stimulation than typical Sermorelin doses. For visceral fat specifically, tesamorelin has the stronger evidence. For general GH optimisation, the choice depends on access and protocol goals.
The FDA approval covers only HIV lipodystrophy. Off-label prescribing of tesamorelin by physicians for other indications including age-related visceral fat is legal but uncommon. Research peptide vendors sell it as a research chemical. In practice, most access is through the research chemical market rather than prescription.
The FDA prescribing information doesn't specify cycling. Clinically, patients use it continuously for the HIV indication with ongoing monitoring. Community protocols typically cycle 3–6 months on with breaks, consistent with general GH secretagogue cycling practices. Continuous use data in non-HIV populations is limited.